147 related articles for article (PubMed ID: 30757917)
1.
Luo J; Zhang B; Cui L; Liu T; Gu Y
Future Oncol; 2019 Apr; 15(12):1303-1311. PubMed ID: 30757917
[No Abstract] [Full Text] [Related]
2. Preserved SCN4B expression is an independent indicator of favorable recurrence-free survival in classical papillary thyroid cancer.
Gong Y; Yang J; Wu W; Liu F; Su A; Li Z; Zhu J; Wei T
PLoS One; 2018; 13(5):e0197007. PubMed ID: 29723302
[TBL] [Abstract][Full Text] [Related]
3. The downregulation of lncRNA EMX2OS might independently predict shorter recurrence-free survival of classical papillary thyroid cancer.
Gu Y; Feng C; Liu T; Zhang B; Yang L
PLoS One; 2018; 13(12):e0209338. PubMed ID: 30576338
[TBL] [Abstract][Full Text] [Related]
4. A novel RNA sequencing-based risk score model to predict papillary thyroid carcinoma recurrence.
He J; Tian Z; Yao X; Yao B; Liu Y; Yang J
Clin Exp Metastasis; 2020 Apr; 37(2):257-267. PubMed ID: 31792675
[TBL] [Abstract][Full Text] [Related]
5. GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy.
Barros-Filho MC; de Mello JBH; Marchi FA; Pinto CAL; da Silva IC; Damasceno PKF; Soares MBP; Kowalski LP; Rogatto SR
Front Endocrinol (Lausanne); 2020; 11():269. PubMed ID: 32425887
[TBL] [Abstract][Full Text] [Related]
6. A Metabolic-associated Nomogram Predicts Recurrence Survival of Thyroid Cancer.
Xi ZH; Ma XX; Chen HY; Yu YH; Li L; Huang T
Curr Med Sci; 2021 Oct; 41(5):1004-1011. PubMed ID: 34510328
[TBL] [Abstract][Full Text] [Related]
7. Low expression of
Yang L; Zhang X; Zhang J; Liu Y; Ji T; Mou J; Fang X; Wang S; Chen J
Future Oncol; 2022 Jan; 18(3):333-348. PubMed ID: 34756116
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of the solute carrier family 7 genes is indicative of poor prognosis in papillary thyroid carcinoma.
Shen L; Qian C; Cao H; Wang Z; Luo T; Liang C
World J Surg Oncol; 2018 Dec; 16(1):235. PubMed ID: 30558624
[TBL] [Abstract][Full Text] [Related]
9. Negative Expression of CPSF2 Predicts a Poorer Clinical Outcome in Patients with Papillary Thyroid Carcinoma.
Sung TY; Kim M; Kim TY; Kim WG; Park Y; Song DE; Park SY; Kwon H; Choi YM; Jang EK; Jeon MJ; Shong YK; Hong SJ; Kim WB
Thyroid; 2015 Sep; 25(9):1020-5. PubMed ID: 26148673
[TBL] [Abstract][Full Text] [Related]
10. Radioactive iodine does not improve overall survival for patients with aggressive variants of papillary thyroid carcinoma less than 2 cm.
Holoubek SA; MacKinney EC; Khokar AM; Kuchta KM; Winchester DJ; Prinz RA; Moo-Young TA
Surgery; 2022 Jan; 171(1):203-211. PubMed ID: 34384604
[TBL] [Abstract][Full Text] [Related]
11. Dynamin 2 Is Correlated with Recurrence and Poor Prognosis of Papillary Thyroid Cancer.
Ren N; Tian Z; Sun H; Lu X
Med Sci Monit; 2020 Aug; 26():e924590. PubMed ID: 32827429
[TBL] [Abstract][Full Text] [Related]
12. Expression of cancer stem cell markers in tall cell variant papillary thyroid cancer identifies a molecular profile predictive of recurrence in classic papillary thyroid cancer.
Beck AC; Rajan A; Landers S; Kelley S; Bellizzi AM; Lal G; Sugg SL; Howe JR; Chan CH; Weigel RJ
Surgery; 2022 Jan; 171(1):245-251. PubMed ID: 34362588
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatic analysis of the prognostic value and potential regulatory network of FOXF1 in papillary thyroid cancer.
Gu Y; Hu C
Biofactors; 2019 Nov; 45(6):902-911. PubMed ID: 31498939
[TBL] [Abstract][Full Text] [Related]
14. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
Jia M; Guo Y; Lu X
Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
[TBL] [Abstract][Full Text] [Related]
15. Differences in the Recurrence and Survival of Patients with Symptomatic and Asymptomatic Papillary Thyroid Carcinoma: An Observational Study of 11,265 Person-Years of Follow-Up.
Kim SH; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
Thyroid; 2016 Oct; 26(10):1472-1479. PubMed ID: 27457917
[TBL] [Abstract][Full Text] [Related]
16. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
[TBL] [Abstract][Full Text] [Related]
17. The value of preoperative antithyroidperoxidase antibody as a novel predictor of recurrence in papillary thyroid carcinoma.
Song E; Oh HS; Jeon MJ; Chung KW; Hong SJ; Ryu JS; Baek JH; Lee JH; Kim WG; Kim WB; Shong YK; Kim TY
Int J Cancer; 2019 Mar; 144(6):1414-1420. PubMed ID: 30357831
[TBL] [Abstract][Full Text] [Related]
18. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
[TBL] [Abstract][Full Text] [Related]
19. A-kinase interacting protein 1 as a potential biomarker of advanced tumor features and increased recurrence risk in papillary thyroid carcinoma patients.
Zhang L; Tao H; Ke K; Ma C
J Clin Lab Anal; 2020 Oct; 34(10):e23452. PubMed ID: 32643206
[TBL] [Abstract][Full Text] [Related]
20. Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
Shi RL; Qu N; Luo TX; Xiang J; Liao T; Sun GH; Wang Y; Wang YL; Huang CP; Ji QH
Thyroid; 2017 Apr; 27(4):537-545. PubMed ID: 27825291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
